Skip to main content
Gaucher DiseaseSanofi· 6 min read· in Health

FDA Approves Venglustat as First Treatment for Neurological Symptoms of Type 3 Gaucher Disease

The U.S. Food and Drug Administration has authorized Sanofi's once-daily oral pill, Infilbray, to treat the progressive cognitive and motor decline associated with a rare genetic disorder. The drug is the first therapy capable of crossing the blood-brain barrier to address the root cause of the disease's neurological manifestations.

By Jun Zhao

Share this story

Listen

The U.S. Food and Drug Administration has approved venglustat, marketed as Infilbray, as the first targeted treatment for the neurological manifestations of Type 3 Gaucher disease. The landmark decision provides a therapeutic option for a rare genetic condition that progressively impairs brain function and motor control.[1][2]

Developed by Sanofi, the once-daily oral pill is authorized for adults and pediatric patients weighing at least 15 kilograms, or about 33 pounds. Until now, medical interventions could only manage the physical symptoms of the disease in the body, leaving the central nervous system entirely unprotected.[1][3]

“For patients with GD3, harmful substances build up in the brain without a way to stop them, but this drug's ability to cross the blood-brain barrier means it can get to the source of the buildup,” acting FDA Commissioner Kyle Diamantas said in a statement.[1]

The approval marks a fundamental shift in how specialists approach lysosomal storage disorders. By successfully delivering an active agent into the brain, researchers have cleared a biological hurdle that has frustrated drug development for decades, offering immediate hope to affected families.[4][6]

The Mechanics Of A Rare Disorder

Gaucher disease is an inherited metabolic condition caused by a mutation in the gene responsible for producing the glucocerebrosidase enzyme. Without sufficient levels of this enzyme, the body cannot properly break down specific fatty sugar molecules known as glycosphingolipids.[3][4]

These unmetabolized fats accumulate inside cells, particularly within macrophages, which then swell into what clinicians call "Gaucher cells." As these cells gather in the spleen, liver, and bone marrow, they cause severe systemic complications, including organ enlargement, severe anemia, and debilitating bone pain.[2][3]

The disease affects roughly one in 40,000 to one in 100,000 live births globally. Clinicians categorize the condition into three primary types based on the presence and severity of neurological involvement, with Type 1 being the most common and largely sparing the brain.[4]

Type 2 is an acute, rapidly progressing neuronopathic form that strikes in infancy and is typically fatal by age two. Type 3, the target of the new approval, is a chronic neuronopathic variant where neurological symptoms emerge in childhood or adolescence and worsen gradually over time.[4]

Patients with Type 3 Gaucher disease face a complex clinical picture. Alongside the physical organ enlargement, they experience progressive neurological decline, which manifests as uncoordinated movements, muscle stiffness, tremors, and distinctive abnormal eye movements, particularly an inability to shift their gaze horizontally.[1][3]

As the disease advances, individuals often develop myoclonic seizures and experience significant cognitive impairment, including memory loss and difficulty processing new information. There are an estimated 1,000 to 1,500 patients living with Type 3 Gaucher disease in the United States.[4]

Crossing The Blood-Brain Barrier

For decades, the standard of care for Gaucher disease has been enzyme replacement therapy, or ERT, administered through intravenous infusions every two weeks. Drugs like imiglucerase effectively supply the missing enzyme to the bloodstream, reducing liver and spleen volumes and resolving blood abnormalities.[2][4]

However, these engineered enzymes are large, complex proteins that cannot penetrate the blood-brain barrier—the tightly packed layer of cells that protects the central nervous system from circulating toxins. Consequently, ERT halts the disease in the body but allows the neurological damage to proceed unchecked.[3][4]

Unlike traditional enzyme replacement therapies, venglustat is designed to cross the blood-brain barrier to target neurological symptoms.

Venglustat takes a fundamentally different approach. Rather than attempting to replace the missing enzyme, it functions as a glucosylceramide synthase inhibitor. The small-molecule drug slows down the body's production of the problematic fatty sugars in the first place, a strategy known as substrate reduction.[2][4]

Because of its molecular size and design, venglustat successfully crosses into the brain tissue. By reducing the synthesis of glycosphingolipids, the drug prevents them from accumulating to toxic levels within the central nervous system, directly addressing the root cause of the neurological decline.[1][3]

“What excites us most is the potential to address critical unmet medical needs,” said Houman Ashrafian, Sanofi’s head of research and development. “A daily pill could make a serious difference for Gaucher patients facing neurological challenges.”[2]

Clinical Trial Outcomes

The FDA based its approval on data from the Phase 3 LEAP2MONO clinical trial, which enrolled 43 patients aged 12 and older. Participants, who had previously been stabilized on standard intravenous enzyme replacement therapy, were evaluated over a 52-week period.[1][2]

Researchers measured neurological function using a composite global score that combined the Scale for Assessment and Rating of Ataxia and the Repeatable Battery for the Assessment of Neuropsychological Status. These tools track motor coordination, memory, and cognitive processing speed.[2][4]

At the end of the year-long study, patients taking venglustat demonstrated statistically significant improvements in their neurological symptoms compared to those who remained on standard enzyme replacement therapy. The data confirmed that the drug was actively altering the disease's trajectory in the brain.[2][4]

Patients taking venglustat demonstrated statistically significant improvements in neurological function over a 52-week period.

Crucially, the oral pill also maintained systemic stability. Patients transitioning to venglustat showed no deterioration in their non-neurological symptoms; their spleen and liver volumes, as well as their hemoglobin levels, remained as well-controlled as they had been on intravenous infusions.[4][5]

The safety profile proved consistent with prior studies of the drug. The most frequently reported adverse events among trial participants receiving venglustat included headaches, nausea, diarrhea, and mild spleen enlargement, occurring in roughly 14 percent of the treatment group.[2][6]

A Shift In Patient Experience

Beyond the clinical metrics, the approval represents a profound lifestyle shift for patients and their caregivers. Transitioning from bi-weekly hospital infusions to a single daily pill restores a degree of independence and normalcy to families managing a complex chronic illness.[2][4]

Patient advocacy groups have emphasized the psychological toll of watching neurological symptoms advance despite diligent adherence to systemic treatments. For years, families have lacked any therapeutic tools to protect their children's cognitive and motor functions.[2]

“Patients living with Type 3 Gaucher disease face a long and difficult road to accurate diagnosis, often going years without answers while neurological manifestations progress,” said Aviva Rosenberg, chief executive of the Gaucher Community Alliance.[2]

Rosenberg noted that the community has monitored the drug's development closely. “Today's Infilbray approval marks a long-awaited advancement for those experiencing devastating neurological symptoms of Type 3 Gaucher disease,” she added.[2]

Illustration: The once-daily oral pill replaces the need for bi-weekly intravenous infusions, offering patients greater independence.

The regulatory clearance also establishes a vital precedent for other lysosomal storage disorders that affect the brain. Demonstrating that a brain-penetrant substrate reduction therapy can safely alter neurological outcomes provides a validated blueprint for researchers targeting similar genetic conditions.[4][6]

Monitoring Long-Term Durability

While the 52-week data secured regulatory approval, clinical researchers will continue to monitor the LEAP2MONO cohort in an open-label extension phase. The ongoing observation aims to determine whether the neurological improvements compound over time or eventually plateau.[2][4]

Specialists are particularly interested in how early intervention might change the disease's natural history. Because neurological damage is often irreversible once established, initiating venglustat as soon as a pediatric patient reaches the 15-kilogram threshold could theoretically prevent cognitive decline entirely.[1][3]

The medical community will also track real-world adherence rates. While a daily pill is less invasive than intravenous therapy, strict daily compliance is essential to maintain the protective drug concentrations within the central nervous system.[4]

The medical community will also track real-world adherence rates.

For now, the introduction of Infilbray closes a critical gap in rare disease care. By successfully bridging the blood-brain barrier, the therapy offers the first tangible defense against the most devastating aspects of Type 3 Gaucher disease, fundamentally rewriting the prognosis for hundreds of patients.[1][2]

Patient Advocacy Groups 35%Clinical Researchers 35%Regulatory Authorities 30%
Patient Advocacy Groups
Emphasize the profound relief of finally having a treatment that addresses cognitive decline and the lifestyle benefits of an oral pill.
Clinical Researchers
Focus on the scientific breakthrough of successfully crossing the blood-brain barrier using substrate reduction therapy.
Regulatory Authorities
Highlight the commitment to addressing critical unmet medical needs in rare and orphan diseases.

Sources

Source coverage

6 outlets

3 viewpoints surfaced

Patient Advocacy Groups 35%Clinical Researchers 35%Regulatory Authorities 30%
  1. [1]U.S. Food and Drug AdministrationRegulatory Authorities

    FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease

    Read on U.S. Food and Drug Administration →
  2. [2]SanofiClinical Researchers

    Press Release: Sanofi's Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease

    Read on Sanofi →
  3. [3]Pharmacy TimesClinical Researchers

    FDA Approves Venglustat, First Treatment for Neurological Symptoms of GD3

    Read on Pharmacy Times →
  4. [4]pharmaphorumPatient Advocacy Groups

    FDA clears Sanofi's Type 3 Gaucher therapy Infilbray

    Read on pharmaphorum →
  5. [5]FirstWord PharmaClinical Researchers

    US clears Sanofi pill for neurological symptoms of Gaucher disease

    Read on FirstWord Pharma →
  6. [6]MorningstarRegulatory Authorities

    Sanofi Gets U.S. Approval for Rare Disease Drug

    Read on Morningstar →
Listen

Comments

Stay informed

Every angle. Every day.

Get Health stories with full source coverage and perspective breakdowns, free every day.